Abstract
In recent years, a variety of treatment methods for Non-small cell lung cancer (NSCLC) have been used, but most of them fail to show significant effect due to the late stage of diagnosis. At present, immunotherapy has become a new way of tumor therapy and attracted wide attention, among which programmed death molecule-1(PD-1) and programmed death ligand-1(PD-L1) have been proved to relate to immune escape in NSCLC, and relevant clinical drugs have shown a clear therapeutic effect. The related drugs can relieve the immune tolerance by blocking the pathway, and play a role in tumor killing. There are now various related drugs. Here, I review the progresses of the mechanistic role of PD-1 pathway in the tumor immune escape and effect of related drugs therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have